One patient has experienced an adverse reaction when using Curaderm
BEC5. The patient experienced some scarring after using Curaderm BEC5
for several months.
On assessment it was established that:
1. The patient had applied Curaderm BEC5 on DRY SPOTS on the skin
even though a dermatologist confirmed that THE PATIENT HAD NO SKIN
CANCER
2. The patient was on corticosteroid therapy which consisted of
prednisone and cortisone.
Prednisone and cortisone therapy have many side effects, including
adverse effects on the skin. Some reported side effects of prednisone
and cortisone taken orally result in the following:
Thinning of the skin, a tendency to bruise easily and extensively with
slight trauma, development of large bruises, decreased muscle mass and
weakness, dry skin, unusual skin growths, immune and inflammatory
suppression, resulting in infections, and wounds take longer to heal.
These steroids break down protein and suppress inflammation, and
initial fibrous tissue is not laid down in the normal way.
Conclusions
* Curaderm BEC5 should be used to treat non melanoma skin cancers
such as: keratosis, keratoacanthoma, basal cell carcinoma and non
metastasised squamous cell carcinoma. Patients should seek medical
advice for their skin lesions before using Curaderm BEC5 and not apply
Curaderm BEC5 on dry spots on the skin.
* Patients on corticosteroid therapy such as prednisone and/or
cortisone should not use Curaderm BEC5.
Tuesday, October 12, 2010
Monday, June 22, 2009
PRESIDENT BARACK OBAMA RECEIVES AN OPEN INVITATION REGARDING REAL HEALTH CARE REFORM IN 2009, SPECIAL REFERENCE TO SKIN CANCER
Dear President Obama
I refer to your email regarding real health care reform in 2009.
I strongly agree that the real reform should uphold the three principles -- it must reduce costs, guarantee choice and ensure quality care for every person.
I have an instance, herewith proposed, which will readily meet your three principles, health care costs reductions, guarantee choice and secure quality care of individuals.
THE CURRENT DILEMMA
In 2001 it was reported that in the US Medicare Skin Cancer Costs hit $1.5 Billion. This was derived from a 5% cross section analysis of the 1996 Medicare billing database.
In a 2008 fact sheet for skin cancer from the American Academy of Dermatology, it was noted that in 2004, the total estimated direct costs associated with the treatment of non-melanoma skin cancers in the US was $1.5 Billion. If according to statistics there were 1.2 million new cases in 2004, then the average cost to treat each skin cancer was about $1,250.
The Skin Cancer Foundation says, the skin cancer disease is the number 1 cancer in men over 50 years, ahead of the combined prostate, lung and colon cancers. In the past 30 years, skin cancer incidence has tripled in woman under age 40 years.
An American Cancer Society Pamphlet shows that an estimated 11,200 people will die of skin cancer this year in the US, 8420 from melanoma and 2780 from other non-melanoma skin cancers.
In the US dermatologists treat about 3/4 of non-melanoma skin cancers. General surgeons and plastic and reconstructive surgeons each treat about 10% of the cases. Surprisingly, primary care physicians only treat about 5% of non-melanoma skin cancers.
Destruction, the least expensive treatment modality, was used in half of all cases; 41% of lesions were excised and 8% were removed with Mohs micrographic surgery.
Average Medicare Part B costs, reflecting office-based but not hospital-based treatment of non-melanoma skin cancer, were $244 for diagnosis, $436 for destruction, $779 for excision and repair, $1416 for Mohs micrographic surgery and $2814 for radiation therapy and these costs were back then in 1996.
Thus, we can conclude that the current treatments of non-melanoma skin cancers are strains on the health care system.
THE ANSWER
In an unpresuming manner I firmly believe that there is a system available that will uphold your three principles.
First a brief background of the proposed system.
In 1987 Dr Bill Cham, a Dutch citizen residing in Australia, and his colleagues published an article in a scientific journal describing the anticancer effects of glycoalkaloids.
During that same year Dr Cham and his colleague Dr Heather Meares published further work showing that these glycoalkaloids were effective in the treatment of human skin cancers.
Since then Dr Cham has enbarked in fundamental and clinical research showing conclusively that these glycoalkaloids had great potential for mankind.
Many independent scientists worldwide have confirmed and extended his observations. Although very promising, substantial more research is required before any claims can be made regarding treatment of terminal internal cancers in man using these glycoalkaloids.
However, this is not the case for the treatment of non-melanoma skin cancers with these glycoalkaloids.
Tremendous amounts of pre-clinical and clinical work have shown that a simple cream containing these glycoalkaloids are very effective and safe when treating such skin cancers.
More recently, in 2008, independent dermatologists at ten hospitals in the United Kingdom have published their clinical studies of over two years in the International Journal of Dermatology. They have concluded that the glycoalkaloid cream has overall efficacy, patient acceptance, low incidence of local adverse events and no systemic side-effects.
These observations confirm the research and the publications by Dr Cham during the last two decades.
For further information, including references of some relevent publications, regarding the glycoalkaloid technology please visit www.curadermbec5global.com
Finally, regarding advocating your three principles of real health care reform in 2009.
REDUCE COSTS
The cost for treating non-melanoma skin cancer with a cream containing the glycoalkaloids is only a small fraction when compared with the existing treatments.
GUARANTEE CHOICE
The treatment of non-melanoma skin cancer with the glycoalkaloids in a cream will be a modality in addition to existing treatments.
SECURE QUALITY CARE
The published studies conclusively show the efficacy of the glycoalkaloid cream. Patients acceptance is good, there is low incidence of local adverse events and there is no systemic side effects. In other words this product is very effective and is very safe.
The cosmetic end result of lesions treated with the cream glycoalkaloids is far superior to any other available treatment. To see pictorial examples of various cases please see publications and visit website www.curadermbec5global.com and go to "Clinical Case Studies"
The intrinsic value of a topical cream formulation known as Curaderm BEC5 to safely and effectively treat skin cancer is immense for the public and the financial reward in terms of saving for the country is great, especially under the current world-wide economic downturn. This glycoalkaloid cream is available now.
I hope this information is of interest to you and sincerely hope that you will adopt the the treatment of the glycoalkaloids in a cream formulation for patients suffering with non-melanoma skin cancer.
Please let me know if you require additional information. The above indicated website gives more detailed information.
I look forward to a rapid reply and wish you all the best in establishing a successful health care reform in 2009.
Yours faithfully
TANIA CHASE (personal assistant of Dr Bill Cham)
I refer to your email regarding real health care reform in 2009.
I strongly agree that the real reform should uphold the three principles -- it must reduce costs, guarantee choice and ensure quality care for every person.
I have an instance, herewith proposed, which will readily meet your three principles, health care costs reductions, guarantee choice and secure quality care of individuals.
THE CURRENT DILEMMA
In 2001 it was reported that in the US Medicare Skin Cancer Costs hit $1.5 Billion. This was derived from a 5% cross section analysis of the 1996 Medicare billing database.
In a 2008 fact sheet for skin cancer from the American Academy of Dermatology, it was noted that in 2004, the total estimated direct costs associated with the treatment of non-melanoma skin cancers in the US was $1.5 Billion. If according to statistics there were 1.2 million new cases in 2004, then the average cost to treat each skin cancer was about $1,250.
The Skin Cancer Foundation says, the skin cancer disease is the number 1 cancer in men over 50 years, ahead of the combined prostate, lung and colon cancers. In the past 30 years, skin cancer incidence has tripled in woman under age 40 years.
An American Cancer Society Pamphlet shows that an estimated 11,200 people will die of skin cancer this year in the US, 8420 from melanoma and 2780 from other non-melanoma skin cancers.
In the US dermatologists treat about 3/4 of non-melanoma skin cancers. General surgeons and plastic and reconstructive surgeons each treat about 10% of the cases. Surprisingly, primary care physicians only treat about 5% of non-melanoma skin cancers.
Destruction, the least expensive treatment modality, was used in half of all cases; 41% of lesions were excised and 8% were removed with Mohs micrographic surgery.
Average Medicare Part B costs, reflecting office-based but not hospital-based treatment of non-melanoma skin cancer, were $244 for diagnosis, $436 for destruction, $779 for excision and repair, $1416 for Mohs micrographic surgery and $2814 for radiation therapy and these costs were back then in 1996.
Thus, we can conclude that the current treatments of non-melanoma skin cancers are strains on the health care system.
THE ANSWER
In an unpresuming manner I firmly believe that there is a system available that will uphold your three principles.
First a brief background of the proposed system.
In 1987 Dr Bill Cham, a Dutch citizen residing in Australia, and his colleagues published an article in a scientific journal describing the anticancer effects of glycoalkaloids.
During that same year Dr Cham and his colleague Dr Heather Meares published further work showing that these glycoalkaloids were effective in the treatment of human skin cancers.
Since then Dr Cham has enbarked in fundamental and clinical research showing conclusively that these glycoalkaloids had great potential for mankind.
Many independent scientists worldwide have confirmed and extended his observations. Although very promising, substantial more research is required before any claims can be made regarding treatment of terminal internal cancers in man using these glycoalkaloids.
However, this is not the case for the treatment of non-melanoma skin cancers with these glycoalkaloids.
Tremendous amounts of pre-clinical and clinical work have shown that a simple cream containing these glycoalkaloids are very effective and safe when treating such skin cancers.
More recently, in 2008, independent dermatologists at ten hospitals in the United Kingdom have published their clinical studies of over two years in the International Journal of Dermatology. They have concluded that the glycoalkaloid cream has overall efficacy, patient acceptance, low incidence of local adverse events and no systemic side-effects.
These observations confirm the research and the publications by Dr Cham during the last two decades.
For further information, including references of some relevent publications, regarding the glycoalkaloid technology please visit www.curadermbec5global.com
Finally, regarding advocating your three principles of real health care reform in 2009.
REDUCE COSTS
The cost for treating non-melanoma skin cancer with a cream containing the glycoalkaloids is only a small fraction when compared with the existing treatments.
GUARANTEE CHOICE
The treatment of non-melanoma skin cancer with the glycoalkaloids in a cream will be a modality in addition to existing treatments.
SECURE QUALITY CARE
The published studies conclusively show the efficacy of the glycoalkaloid cream. Patients acceptance is good, there is low incidence of local adverse events and there is no systemic side effects. In other words this product is very effective and is very safe.
The cosmetic end result of lesions treated with the cream glycoalkaloids is far superior to any other available treatment. To see pictorial examples of various cases please see publications and visit website www.curadermbec5global.com and go to "Clinical Case Studies"
The intrinsic value of a topical cream formulation known as Curaderm BEC5 to safely and effectively treat skin cancer is immense for the public and the financial reward in terms of saving for the country is great, especially under the current world-wide economic downturn. This glycoalkaloid cream is available now.
I hope this information is of interest to you and sincerely hope that you will adopt the the treatment of the glycoalkaloids in a cream formulation for patients suffering with non-melanoma skin cancer.
Please let me know if you require additional information. The above indicated website gives more detailed information.
I look forward to a rapid reply and wish you all the best in establishing a successful health care reform in 2009.
Yours faithfully
TANIA CHASE (personal assistant of Dr Bill Cham)
Sunday, March 8, 2009
Re: Eggplant mania for cancer
The article Eggplant mania for cancer by Orac really suits Respectful Insolence, not that the Eggplant mania for cancer is the Insolence but that the ramblings of Orac are.
If Orac had done proper research the majority of his ramblings would have been proven to be incorrect. The statements by Dr Cham on his research findings are factual, and by Orac's own definition, cannot be insolent.
I suggest that Orac familiarise him/her self with information available on www.curadermbec5global.com
Just to identify and correct Orac's biased misgivings regarding his article let me select some of his/her shortcomings.
Regarding cancer cures with Curaderm BEC5
Patients treated with Curaderm BEC5 have been followed up for over 5 years and even 10 years post treatment. There were no recurrences. By medical definition if a treated health problem does not recur after 5 years treatment it can be considered that the treatment is a cure.
The mode of action of the BEC glycoalkaloids (extracted from the Devil's Apple fruit or eggplant) has now been evaluated and confirmed by independent scientists throughout the world (see Research Publications when visiting www.curadermbec5global.com). It appears from such publications in scientific journals that BEC glycoalkaloids specifically destroy cancer cells without harming normal cells . When this occurs on the skin whilst treating skin cancers, the area where the cancers were prior to treatment with Curaderm BEC5 regenerates with normal skin replacing the now eliminated skin cancer cells. This is not an unbeliavable claim but factual (see wide range of before, during and after treatment with Curaderm BEC5 lesions on www.curadermbec5global.com "clinical case studies".
The statements of Orac regarding what Dr Cham says, are incorrect. These statements were made, not by Dr Cham, but by respected independent peers such as Dr Jonothan Wright, a highly respected medical doctor who resides in Seattle USA.
Regarding Orac's statement "Silly" me. A search of "eggplant" and "skin cancer" revealed two references. "Silly" Orac indeed. If he/she is delving into scientific information Orac must be diligent, unbiased and could have requested information from Dr Cham before making a fool of him/her self.
Regarding Phases I to IV clinical trials
Again I refer to www.curadermbec5global.com Orac's simplistic statement "simple surgical excision is curative (now because it suits Orac this cure term is permitted) as they say, nothing heals like surgical steel". This statement is in direct contrast to independent published work where it has been reported that 30-67% of BCC (basal cell carcinoma) cases treated by surgery recur.
Again see www.curadermbec5global.com Research Publications ->->->->-> Publications/Medical Research ->->->->-> Sussman, L.A.E and Liggins, D.F. (1996). Incompletely excised basal cell carcinoma: a management dilemma? Aust.NZ.J. Surg. 66,276-278. http://www.ncbi.nlm.nih.gov/pubmed/8634041?dopt=Citation
Orac should also be aware that the other group he/she refers to that actually did a clinical trial using a related compound with reportedly significant efficacy had indeed used Curaderm BEC5 manufactured and supplied to that group by Dr Cham for their clinical trials.
It is also interesting to note that Orac is a depressive person since he/she is so easily depressed by eagerly and in a biased fashion reporting information that is incorrect. All Orac had to do was to request information directly from Dr Cham before doing him/her self, science and the public much injustice.
Subscribe to:
Posts (Atom)
